过敏诊断市场（按测试类型、技术、过敏原类型和最终用户划分）—2025-2032 年全球预测

预计到 2032 年，过敏诊断市场规模将成长至 94.6 亿美元，复合年增长率为 5.98%。

简述影响现代过敏诊断策略的不断变化的临床需求和技术进步

过敏诊断处于临床需求与技术创新的交汇点，其驱动力来自过敏性疾病盛行率的上升、临床医生诊断意识的提升以及患者对针对性管理策略的需求。临床医生越来越依赖精准的诊断途径来区分致敏和临床相关过敏，这使得在门诊和住院环境中进行可重复、高品质的检测变得尤为重要。同时，检测技术和实验室自动化的进步正在拓展可行的检测方案，从而实现更细緻的解读，并支持精准的治疗方法。

医疗保健系统也在应对减少可避免的急诊就诊和改善慢性病管理的压力，将准确快速的过敏诊断定位为更广泛护理途径中经济高效的临床工具。付款人和采购团队要求提供临床效用、营运效率以及与电子健康记录互通性的证据，这促使供应商和实验室优先考虑检验、标准化和报告清晰度。总而言之，这些趋势明确了希望投资和采用过敏诊断解决方案的利害关係人的当务之急。

临床、技术和操作趋势的融合从根本上重塑了诊断途径并实现了个人化过敏药物。

技术日趋成熟、临床模式不断转变以及医疗服务模式的不断发展，正在显着改变过敏诊断领域。分子诊断和成分解析诊断已从小众应用走向更广泛的临床应用，使临床医生能够分析复杂的致敏情况，并更好地预测严重过敏反应的风险。同时，多重平台的出现，加上侦测灵敏度和特异性的提升，正在减少诊断的不确定性，缩短治疗决策的路径。

在营运方面，诊断实验室正在采用更高程度的自动化和数位化集成，以提高通量、缩短週转时间，同时支援一致的品管。即时检验计划和分散式检测路径反映了将适当的护理转移到更贴近患者的更广泛趋势。此外，诊断结果与临床决策支援工具的整合正变得越来越普遍，使临床医生能够根据检测结果、合併症概况和暴露史获得循证建议。这种转变正在将过敏诊断的作用从确认性检测转变为主动实现个人化护理。

评估 2025 年关税格局将如何重塑诊断价值链的供应链、采购行为和区域製造策略

政策和贸易行动可能会对整个诊断供应链产生重大的连锁反应，而2025年宣布的关税调整的累积影响将波及製造、分销和实验室运营的各个环节。对进口试剂、仪器零件和耗材征收关税可能会提高依赖海外供应商的製造商的边际生产成本，从而导致标价上涨和合约压力。对于实验室和最终用户而言，这更凸显了供应链韧性、库存规划和长期供应商协议谈判的重要性。

此外，关税可能会推动生产和采购的在地化，促使跨国製造商重新评估其采购布局，并考虑近岸外包或双重采购策略以降低风险。同时，医院、门诊中心和诊断网络内的采购团队可能会将采购重点转移到拥有国内生产能力或已製定关税减免政策的供应商。这些调整可能会加速能够吸收成本波动并维持服务水准的供应商之间的整合，同时迫使规模较小的供应商和试剂供应商优化营运或建立策略联盟以保持市场进入。

有针对性的细分洞察，将机会与测试方式、检测技术、过敏原和最终用户业务优先事项联繫起来

细分市场洞察对于客製化产品开发、商业化和应用策略至关重要。基于检测类型的诊断途径范围广泛，从基于皮肤的方法（例如皮内测试和斑贴测试）到基于血清的方法（包括血清特异性IgE检测和皮肤点刺测试）。对于血清分析，化学冷光免疫检测和酵素结合免疫吸附检测法与传统的放射性过敏原检测法并存，每种方法在通量、灵敏度和实验室相容性方面各有优缺点。化学冷光平台往往强调自动化和灵敏度，酵素结合免疫吸附分析为中型实验室提供灵活性和成本效益，萤光酶联免疫分析根据配置提供多路復用优势，而放射性过敏原吸附分析在现有工作流程持续存在的情况下仍然具有重要意义。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 基层医疗机构越来越多地采用照护现场过敏检测设备
• 多重免疫检测平台的快速成长提供了更广泛的过敏原组
• 整合人工智慧和机器学习，提高过敏测试的诊断准确性
• 越来越多地采用成分解析诊断技术，以便对个别过敏原进行分析，从而进行标靶治疗
• 扩展家庭过敏检测套组，支援透过智慧型手机连接进行远端患者监护
• 新兴分子诊断技术可准确辨识过敏表位
• 数位医疗基础设施的改善正在推动基于远端医疗的过敏咨询需求
• 不断变化的监管环境影响创新过敏诊断解决方案的核准途径

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章过敏诊断市场（依测试类型）

• 皮内试验
• 斑贴试验
• 血清特异性IgE检测
  • 化学冷光免疫检测
  • 酵素结合免疫吸附试验
  • 放射性过敏原吸附试验
• 皮肤点刺试验

9. 过敏诊断市场（依技术）

• 化学冷光免疫检测
• 酵素结合免疫吸附试验
• 萤光酵素免疫分析法
• 放射性过敏原吸附试验

第 10 章过敏诊断市场（依过敏原类型）

• 接触过敏原
• 药物过敏原
• 食物过敏原
• 吸入性过敏原

第 11 章过敏诊断市场（依最终用户）

• 门诊治疗中心
• 诊断实验室
• 医院和诊所

第十二章过敏诊断市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章过敏诊断市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 过敏诊断市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Siemens Healthineers AG
  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Hycor Biomedical, LLC
  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Eurofins Scientific SE
  • Quest Diagnostics Incorporated
  • Stallergenes Greer, Inc.

The Allergy Diagnostics Market is projected to grow by USD 9.46 billion at a CAGR of 5.98% by 2032.

A concise orientation to the evolving clinical imperatives and technological advances shaping modern allergy diagnostic strategies

Allergy diagnostics sits at the nexus of clinical need and technological innovation, driven by rising prevalence of allergic conditions, greater diagnostic awareness among clinicians, and patient demand for targeted management strategies. Clinicians increasingly rely on precise diagnostic pathways to distinguish sensitization from clinically relevant allergy, and this has elevated the importance of reproducible, high-quality testing across outpatient and hospital settings. Concurrently, advances in assay technologies and laboratory automation have expanded the range of viable options, enabling more nuanced interpretations and supporting precision therapeutics.

Healthcare systems are also responding to pressures to reduce avoidable emergency visits and improve chronic disease management, which positions accurate and rapid allergy diagnostics as a cost-effective clinical tool in broader care pathways. Payers and procurement teams are seeking evidence of clinical utility, operational efficiency, and interoperability with electronic health records, prompting vendors and laboratories to prioritize validation, standardization, and reporting clarity. Taken together, these dynamics frame the immediate priorities for stakeholders seeking to invest in or adopt allergy diagnostic solutions.

How converging clinical, technological, and operational trends are fundamentally reshaping diagnostic pathways and enabling personalized allergy care

The landscape of allergy diagnostics is undergoing transformative shifts prompted by technological maturation, changing clinical paradigms, and evolving healthcare delivery models. Molecular and component-resolved diagnostics have moved from niche applications toward broader clinical acceptance, enabling clinicians to parse complex sensitization profiles and better predict risk for severe reactions. At the same time, improvements in assay sensitivity and specificity, alongside growing availability of multiplex platforms, are reducing diagnostic ambiguity and shortening the route to therapeutic decisions.

Operationally, diagnostic laboratories are adopting higher degrees of automation and digital integration, which improves throughput and reduces turnaround time while supporting consistent quality control. The rise of point-of-care initiatives and decentralized testing pathways reflects a broader trend toward shifting appropriate care closer to patients. Additionally, the integration of diagnostic outputs with clinical decision support tools is gaining traction, providing clinicians with evidence-based recommendations informed by test results, comorbidity profiles, and exposure histories. These convergent shifts are recasting the role of allergy diagnostics from confirmatory testing to a proactive enabler of personalized care.

Assessing how the 2025 tariff landscape will reshape supply chains, procurement behaviors, and regional manufacturing strategies across the diagnostics value chain

Policy actions and trade measures can have substantial ripple effects across the diagnostics supply chain, and the cumulative impact of tariff adjustments announced for 2025 will be observed across manufacturing, distribution, and laboratory operations. Tariffs on imported reagents, instrument components, and consumables raise the marginal cost of production for manufacturers that rely on international suppliers, which can translate into higher list prices and contracting pressures. For laboratories and end users, this increases the importance of supply chain resilience, inventory planning, and the negotiation of long-term supplier agreements.

Moreover, tariffs can incentivize regionalization of production and procurement, prompting multinational manufacturers to reassess sourcing footprints and consider nearshoring or dual-sourcing strategies to mitigate exposure. In parallel, procurement teams within hospitals, ambulatory centers, and diagnostics networks may shift purchasing priorities toward suppliers with domestic manufacturing capabilities or established tariff-mitigation measures. Over time, these adjustments may accelerate consolidation among suppliers who can absorb cost variability and maintain service levels, while smaller vendors and reagent suppliers face increased pressure to optimize operations or form strategic alliances to preserve market access.

Targeted segmentation insights linking test modalities, assay technologies, allergen categories, and end-user operational priorities to commercial opportunities

Segment insights are essential for tailoring product development, commercialization, and adoption strategies. Based on test type, diagnostic pathways range from skin-based modalities such as intradermal and patch testing to serum-based approaches including serum-specific IgE assays and skin prick testing; within serum analyses, chemiluminescence immunoassay and enzyme-linked immunosorbent assay methods coexist with legacy radioallergosorbent techniques, each offering distinct trade-offs in throughput, sensitivity, and laboratory compatibility. Based on technology, assay selection further differentiates the market because chemiluminescence platforms tend to favor automation and sensitivity, enzyme-linked immunosorbent assays deliver flexibility and cost efficiency for mid-volume labs, fluorescent enzyme immunoassays offer multiplexing advantages in some configurations, and radioallergosorbent methods remain relevant where established workflows persist.

Based on allergen type, diagnostic requirements vary substantially: contact allergens and drug allergens often require tailored exposure histories and specialized panels, food allergens demand high specificity to minimize unnecessary avoidance, and inhalant allergens benefit from well-validated component testing to guide immunotherapy. Based on end user, operational imperatives differ between ambulatory care centers prioritizing rapid, clinic-friendly workflows; diagnostic laboratories focusing on throughput, reproducibility, and result interpretation; and hospitals and clinics that integrate diagnostics into acute and chronic care pathways and require robust reporting for complex patients. These segmentation lenses highlight where clinical demand, laboratory capability, and commercial models intersect and where targeted investment can drive adoption.

How divergent regional clinical practices, regulatory landscapes, and infrastructure investments create distinct adoption pathways across global markets

Regional dynamics influence both clinical practice and commercial strategies, requiring nuanced approaches to product design, regulatory engagement, and channel management. In the Americas, robust clinical adoption of advanced serum-based assays is paired with concentrated laboratory networks and strong payer scrutiny, which together demand demonstrable clinical utility and efficient reimbursement pathways. In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and variable laboratory capacity mean that flexible product configurations, local partnerships, and support for decentralized testing can accelerate uptake, while regional clinical guidelines influence which allergen panels and assay formats are prioritized. In Asia-Pacific, rapid healthcare infrastructure investment, a growing prevalence of allergic conditions in urban centers, and diverse regulatory pathways create opportunities for both high-throughput centralized laboratories and point-of-care solutions adapted to local clinical workflows.

Taken together, these regional distinctions inform commercialization strategies, regulatory planning, and supply chain design, underscoring the importance of tailored evidence generation, localized service models, and partnerships with regional laboratory networks to achieve sustainable market penetration.

Key competitive behaviors and strategic priorities that determine which diagnostic providers will lead in laboratory adoption and clinical guideline integration

Competitive dynamics in allergy diagnostics are shaped by a mix of large diversified diagnostics firms, specialized allergy assay manufacturers, and agile niche players that focus on innovation or regional distribution. Established manufacturers invest in automation, multiplexing, and digital result interpretation to differentiate their portfolios and to meet laboratory demands for efficiency and integrated reporting. Specialized companies emphasize proprietary assay chemistries or clinical evidence supporting component-resolved diagnostics in order to drive adoption among allergists and tertiary care centers. Additionally, contract manufacturers and reagent suppliers play a critical role in maintaining supply continuity, particularly as laboratories seek partners capable of supporting validation and quality assurance under evolving regulatory expectations.

Strategic behaviors to watch include investments in partnerships with clinical networks and pharmacy chains for broader access, alliances with laboratory information system vendors to enhance result interoperability, and targeted evidence generation programs to secure favorable placement in clinical guidelines. Consolidation activity can be expected where scale enables improved pricing, distribution reach, and the ability to invest in next-generation assay development. New entrants that couple strong clinical data with scalable manufacturing and regulatory acumen will be well positioned to disrupt legacy business models.

Prioritized strategic initiatives for executives to strengthen evidence, interoperability, supply resilience, and go-to-market precision in allergy diagnostics

Industry leaders should prioritize a set of actionable initiatives to translate market dynamics into durable competitive advantage. First, invest in robust clinical evidence generation that demonstrates not only analytical performance but also clinical utility in guiding management decisions and reducing downstream healthcare utilization. Second, pursue platform interoperability and strong integration with laboratory information systems and electronic health records to streamline clinician workflows and enable value capture through decision support. Third, diversify supply chains and consider dual-sourcing or regional manufacturing arrangements to mitigate tariff exposure and ensure continuity of supply for critical reagents and instrument components.

Furthermore, adopt customer segmentation strategies that align commercial resources with the operational realities of ambulatory centers, high-throughput diagnostic laboratories, and integrated hospital systems. Complement product investments with scalable service offerings such as training, proficiency programs, and outcome tracking that lower adoption barriers. Finally, explore partnerships with therapeutics providers and allergy clinics to create bundled care pathways that link diagnostics to targeted interventions, thereby enhancing value propositions for payers and providers.

A transparent mixed-methods research approach integrating stakeholder interviews, regulatory review, and technical validation to underpin strategic recommendations

This analysis synthesizes findings derived from a rigorous mixed-methods research approach combining primary qualitative interviews with laboratory directors, practicing allergists, procurement leads, and industry executives alongside systematic secondary review of peer-reviewed literature, regulatory guidances, and technical documentation from assay manufacturers. Primary research emphasized triangulation across stakeholder groups to validate clinical workflows, assay preferences, and adoption barriers. Secondary sources provided context on technology performance characteristics, reimbursement environments, and historic regulatory precedents, which informed interpretation of stakeholder input and scenario development.

Data validation included cross-checking assay attributes and claimed performance characteristics against device labeling and regulatory summaries, while methodological transparency was maintained through clear documentation of inclusion criteria, interview protocols, and synthesis techniques. Limitations include variability across regional regulatory regimes and the evolving nature of trade policies, which may affect supply chain dynamics; these factors were addressed through scenario analysis and sensitivity checks to ensure robustness of recommendations. The result is a pragmatic evidence base designed to support strategic planning without relying on speculative forecasts.

Synthesis of actionable insights highlighting where technological advances, clinical expectations, and supply constraints intersect to inform strategic decisions

Allergy diagnostics is positioned at an inflection point where improved assay technologies, evolving clinical expectations, and supply chain realities converge to redefine how allergic disease is identified and managed. Precision in testing is enabling more effective patient stratification and targeted therapeutic pathways, while operational innovations are expanding capacity and improving turnaround. However, external pressures including trade policy shifts and regional heterogeneity in regulatory and reimbursement frameworks require proactive strategies around supply chain resilience, evidence generation, and localized commercialization.

Looking ahead, stakeholders who align product design with demonstrable clinical value, ensure interoperability with clinical systems, and adopt flexible manufacturing and distribution models will be best placed to capture opportunity and sustain adoption. Strategic collaboration between diagnostic providers, clinical networks, and payers will be crucial to translate diagnostic advances into measurable improvements in care pathways and patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Increasing adoption of point-of-care allergy testing devices in primary care settings
• 5.2. Rapid growth of multiplex immunoassay platforms offering expanded allergen panels
• 5.3. Integration of artificial intelligence and machine learning for enhanced diagnostic accuracy in allergy testing
• 5.4. Rising prevalence of component-resolved diagnostics enabling personalized allergen profiling for targeted treatment
• 5.5. Expansion of home-based allergy testing kits with smartphone connectivity for remote patient monitoring
• 5.6. Emergence of molecular diagnostic techniques for precise identification of allergenic epitopes
• 5.7. Growing demand for telemedicine-based allergy consultations driven by improved digital health infrastructure
• 5.8. Regulatory landscape evolution impacting approval pathways for innovative allergy diagnostic solutions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Allergy Diagnostics Market, by Test Type

• 8.1. Intradermal Test
• 8.2. Patch Test
• 8.3. Serum-Specific IgE Test
  • 8.3.1. Chemiluminescence Immunoassay
  • 8.3.2. Enzyme-Linked Immunosorbent Assay
  • 8.3.3. Radioallergosorbent Test
• 8.4. Skin Prick Test

9. Allergy Diagnostics Market, by Technology

• 9.1. Chemiluminescence Immunoassay
• 9.2. Enzyme-Linked Immunosorbent Assay
• 9.3. Fluorescent Enzyme Immunoassay
• 9.4. Radioallergosorbent Test

10. Allergy Diagnostics Market, by Allergen Type

• 10.1. Contact Allergen
• 10.2. Drug Allergen
• 10.3. Food Allergen
• 10.4. Inhalant Allergen

11. Allergy Diagnostics Market, by End User

• 11.1. Ambulatory Care Centers
• 11.2. Diagnostic Laboratories
• 11.3. Hospitals & Clinics

12. Allergy Diagnostics Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Allergy Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Allergy Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Siemens Healthineers AG
  • 15.3.2. Abbott Laboratories
  • 15.3.3. Beckman Coulter, Inc.
  • 15.3.4. Hycor Biomedical, LLC
  • 15.3.5. Thermo Fisher Scientific Inc.
  • 15.3.6. Becton Dickinson and Company
  • 15.3.7. Bio-Rad Laboratories, Inc.
  • 15.3.8. Eurofins Scientific SE
  • 15.3.9. Quest Diagnostics Incorporated
  • 15.3.10. Stallergenes Greer, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. ALLERGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. ALLERGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ALLERGY DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INTRADERMAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY PATCH TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY SKIN PRICK TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENT ENZYME IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY RADIOALLERGOSORBENT TEST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY CONTACT ALLERGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DRUG ALLERGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY FOOD ALLERGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY INHALANT ALLERGEN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 126. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 127. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 128. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 129. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 130. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 131. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 132. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 133. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 134. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 135. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 136. AMERICAS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 137. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 140. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 141. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 142. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 143. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 144. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 145. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 146. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 147. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 148. NORTH AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 149. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 152. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 153. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 154. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 155. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 156. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 157. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 158. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 159. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 160. LATIN AMERICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 173. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 176. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 177. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 178. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 179. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 180. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 181. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 182. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 183. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 184. EUROPE ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 185. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 188. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 189. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 190. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 192. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 193. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 194. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 195. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 196. MIDDLE EAST ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 197. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 200. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 201. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 202. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 203. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 204. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 205. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 206. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 207. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. AFRICA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 212. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 213. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 214. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 215. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 216. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 217. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 218. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 219. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 220. ASIA-PACIFIC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 226. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 227. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 228. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 229. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 230. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 231. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 232. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 233. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. ASEAN ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 238. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 239. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 240. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 241. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 242. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 243. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 244. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 245. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 246. GCC ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 247. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 248. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 249. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 250. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 251. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 252. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 253. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 254. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 255. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 256. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 257. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 258. EUROPEAN UNION ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 259. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 260. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 261. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 262. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 263. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 264. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 265. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 266. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 267. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 268. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 269. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 270. BRICS ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 271. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 274. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 275. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 276. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 277. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 278. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 279. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 280. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 281. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 282. G7 ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 283. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 286. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 287. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 288. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 289. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 290. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 291. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 292. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 293. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 294. NATO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 295. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 296. GLOBAL ALLERGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 297. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 298. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 299. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 300. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 301. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 302. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 303. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 304. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 305. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 306. UNITED STATES ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 307. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 308. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 309. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 310. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 311. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 312. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 313. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 314. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 315. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 316. CANADA ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 317. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 318. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
• TABLE 319. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2018-2024 (USD MILLION)
• TABLE 320. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY SERUM-SPECIFIC IGE TEST, 2025-2032 (USD MILLION)
• TABLE 321. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 322. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 323. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2018-2024 (USD MILLION)
• TABLE 324. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY ALLERGEN TYPE, 2025-2032 (USD MILLION)
• TABLE 325. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 326. MEXICO ALLERGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 327. BRAZIL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 328. BRAZIL ALLERGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)

TABLE 32